83 related articles for article (PubMed ID: 11381117)
1. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex.
Heemskerk MH; de Paus RA; Lurvink EG; Koning F; Mulder A; Willemze R; van Rood JJ; Falkenburg JH
Proc Natl Acad Sci U S A; 2001 Jun; 98(12):6806-11. PubMed ID: 11381117
[TBL] [Abstract][Full Text] [Related]
2. Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.
Schirmer D; Grünewald TG; Klar R; Schmidt O; Wohlleber D; Rubío RA; Uckert W; Thiel U; Bohne F; Busch DH; Krackhardt AM; Burdach S; Richter GH
Oncoimmunology; 2016 Jun; 5(6):e1175795. PubMed ID: 27471654
[TBL] [Abstract][Full Text] [Related]
3. Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases.
Lucero OM; Lee JA; Bowman J; Johnson K; Sapparapu G; Thomas JK; Fan G; Chang BH; Thiel-Klare K; Eide CA; Okada C; Palazzolo M; Lind E; Kosaka Y; Druker BJ; Lydon N; Bowers PM
Clin Cancer Res; 2023 Oct; 29(20):4230-4241. PubMed ID: 37199721
[TBL] [Abstract][Full Text] [Related]
4. Dual Valpha T cells.
Elliott JI
Cell Mol Life Sci; 1999 Oct; 56(1-2):143-54. PubMed ID: 11213254
[TBL] [Abstract][Full Text] [Related]
5. A class-mismatched TCR bypasses MHC restriction via an unorthodox but fully functional binding geometry.
Singh NK; Alonso JA; Devlin JR; Keller GLJ; Gray GI; Chiranjivi AK; Foote SG; Landau LM; Arbuiso AG; Weiss LI; Rosenberg AM; Hellman LM; Nishimura MI; Baker BM
Nat Commun; 2022 Nov; 13(1):7189. PubMed ID: 36424374
[TBL] [Abstract][Full Text] [Related]
6. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.
Luo X; Cui H; Cai L; Zhu W; Yang WC; Patrick M; Zhu S; Huang J; Yao X; Yao Y; He Y; Ji Y
Front Immunol; 2020; 11():623. PubMed ID: 32425926
[TBL] [Abstract][Full Text] [Related]
7. Regulation of NK-Cell Function by HLA Class II.
Niehrs A; Altfeld M
Front Cell Infect Microbiol; 2020; 10():55. PubMed ID: 32133304
[TBL] [Abstract][Full Text] [Related]
8. Targeting cancers through TCR-peptide/MHC interactions.
He Q; Jiang X; Zhou X; Weng J
J Hematol Oncol; 2019 Dec; 12(1):139. PubMed ID: 31852498
[TBL] [Abstract][Full Text] [Related]
9. HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers.
Nyanhete TE; Frisbee AL; Bradley T; Faison WJ; Robins E; Payne T; Freel SA; Sawant S; Weinhold KJ; Wiehe K; Haynes BF; Ferrari G; Li QJ; Moody MA; Tomaras GD
Sci Rep; 2019 Jul; 9(1):10165. PubMed ID: 31308388
[TBL] [Abstract][Full Text] [Related]
10. Safety and Tolerability of Adoptive Cell Therapy in Cancer.
Wolf B; Zimmermann S; Arber C; Irving M; Trueb L; Coukos G
Drug Saf; 2019 Feb; 42(2):315-334. PubMed ID: 30649750
[TBL] [Abstract][Full Text] [Related]
11. PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy.
Luk SJ; van der Steen DM; Hagedoorn RS; Jordanova ES; Schilham MW; Bovée JV; Cleven AH; Falkenburg JF; Szuhai K; Heemskerk MH
Oncoimmunology; 2018; 7(12):e1507600. PubMed ID: 30524904
[TBL] [Abstract][Full Text] [Related]
12. The intersection of affinity and specificity in the development and optimization of T cell receptor based therapeutics.
Riley TP; Baker BM
Semin Cell Dev Biol; 2018 Dec; 84():30-41. PubMed ID: 30449534
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic CD8
Junqueira C; Barbosa CRR; Costa PAC; Teixeira-Carvalho A; Castro G; Sen Santara S; Barbosa RP; Dotiwala F; Pereira DB; Antonelli LR; Lieberman J; Gazzinelli RT
Nat Med; 2018 Sep; 24(9):1330-1336. PubMed ID: 30038217
[TBL] [Abstract][Full Text] [Related]
14. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
15. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.
Jahn L; van der Steen DM; Hagedoorn RS; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(47):77021-77037. PubMed ID: 27776339
[TBL] [Abstract][Full Text] [Related]
16. Antiviral CD8
Ranasinghe S; Lamothe PA; Soghoian DZ; Kazer SW; Cole MB; Shalek AK; Yosef N; Jones RB; Donaghey F; Nwonu C; Jani P; Clayton GM; Crawford F; White J; Montoya A; Power K; Allen TM; Streeck H; Kaufmann DE; Picker LJ; Kappler JW; Walker BD
Immunity; 2016 Oct; 45(4):917-930. PubMed ID: 27760342
[TBL] [Abstract][Full Text] [Related]
17. Class II-Restricted CD8s: New Lessons Violate Old Paradigms.
Migueles SA; Connors M
Immunity; 2016 Oct; 45(4):712-714. PubMed ID: 27760334
[TBL] [Abstract][Full Text] [Related]
18. A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.
Jahn L; Hagedoorn RS; van der Steen DM; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(44):71536-71547. PubMed ID: 27689397
[TBL] [Abstract][Full Text] [Related]
19. CD4(+) and CD8(+) TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells.
Nakatsugawa M; Rahman MA; Yamashita Y; Ochi T; Wnuk P; Tanaka S; Chamoto K; Kagoya Y; Saso K; Guo T; Anczurowski M; Butler MO; Hirano N
Sci Rep; 2016 Mar; 6():23821. PubMed ID: 27030642
[TBL] [Abstract][Full Text] [Related]
20. HLA monomers as a tool to monitor indirect allorecognition.
Breman E; van Miert PP; van der Steen DM; Heemskerk MH; Doxiadis II; Roelen D; Claas FH; van Kooten C
Transplantation; 2014 Jun; 97(11):1119-27. PubMed ID: 24798312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
